| findings unveil a potential tumor-suppressor role of ERbeta in ovarian carcinogenesis, which could be of potential clinical relevance for the selection of the most appropriate treatment for patients | ovarian, |
| ERbeta1 signaling may have pro-differentiation and tumor suppressive function in medulloblastomas | medulloblastomas, |
| Results confirm the importance of ERbeta1 as a tumor suppressor in breast cancer an emphasizes that its nuclear expression is associated with improved outcome in women treated with adjuvant tamoxifen. | breast, |
| Using ERbeta isoform-specific PCR screening, study found that glioblastoma (GBM) cells predominantly express ERbeta1 and ERbeta5, along with low levels of ERbeta2 and ERbeta4. Work confirms the tumor-suppressive potential of ERbeta1 and reveals the acquired oncogenic ability of ERbeta5 in GBM cells. ERbeta isoform status and their unique interactions with oncogenic pathways may have important implications in GBM progre... | GBM,glioblastoma, |
| ERbeta is a tumor suppressor gene in the Ventral prostate and mammary gland where its loss increases the activity androgen receptor and ERalpha, respectively. | prostate, |
| These observations support the notion that ERbeta is a tumour suppressor and is exploitable in terms of cancer prevention, improving therapeutic response or predicting disease progression. | None |
| Pubertal physical activity up-regulates tumor suppressor genes BRCA1, p53 and ER-beta, and reduced ER-alpha/ER-beta ratio in the mammary gland | None |
| ERbeta exerts antiproliferative effects both on MCF-10A and MCF-7 cells in a ligand- and ERalpha-independent manner by regulation of p21/WAF or cyclin A2 gene expression. ERbeta acts as a tumor suppressor in mammary epithelium. | None |
| ERbeta acting as a tumor suppressor is of high potential relevance to prediction of disease progression. | None |
| results show that ER-beta suppresses HIF-1alpha-mediated transcription via ARNT down-regulation, which may account for the tumour suppressive function of ER-beta | None |
| Estrogen-activated ERbeta acts as a tumor suppressor. | None |
| MTA1 dysregulation in a subset of salivary gland cancer might promote aggressive phenotypes by compromising the tumor suppressor activity of ERbeta | None |
| Estrogen Receptor Beta (ER?): A Ligand Activated Tumor Suppressor | None |
| These findings suggest that at least part of the oncogenic effects of ERbeta2 is mediated by HIF-1alpha and that targeting of this ERbeta2 - HIF-1alpha interaction may be a strategy to treat prostate cancer. | prostate, |